Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Karn

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 11, 2021
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trialsJenny Furlanetto, Frederik Marmé, Sabine Seiler, et al.
Breast Cancer Research : BCR|September 25, 2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersGiampaolo Bianchini, Lajos Pusztai, Thomas Karn, et al.
Breast Cancer Research : BCR|September 24, 2024
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancerBruno Valentin Sinn, Katharina Sychra, Michael Untch, et al.
BMC Cancer|August 15, 2021
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancerChristine Stürken, Volker Möbus, Karin Milde-Langosch, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive studyAurelia Noske, Volker Möbus, Karsten Weber, et al.
Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
Breast Cancer Research and Treatment|September 7, 2017
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trialsMarion T van Mackelenbergh, Carsten Denkert, Valentina Nekljudova, et al.
Journal of the American Heart Association|November 16, 2020
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 TrialAlexandra Maria Rüger, Andreas Schneeweiss, Sabine Seiler, et al.
International Journal of Molecular Sciences|February 11, 2023
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry ImagingJuliana Pereira Lopes Gonçalves, Christine Bollwein, Aurelia Noske, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|June 11, 2021
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trialsJenny Furlanetto, Frederik Marmé, Sabine Seiler, et al.
Breast Cancer Research : BCR|September 25, 2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersGiampaolo Bianchini, Lajos Pusztai, Thomas Karn, et al.
Breast Cancer Research : BCR|September 24, 2024
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancerBruno Valentin Sinn, Katharina Sychra, Michael Untch, et al.
BMC Cancer|August 15, 2021
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancerChristine Stürken, Volker Möbus, Karin Milde-Langosch, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2019
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive studyAurelia Noske, Volker Möbus, Karsten Weber, et al.
Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
Breast Cancer Research and Treatment|September 7, 2017
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trialsMarion T van Mackelenbergh, Carsten Denkert, Valentina Nekljudova, et al.
Journal of the American Heart Association|November 16, 2020
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 TrialAlexandra Maria Rüger, Andreas Schneeweiss, Sabine Seiler, et al.
International Journal of Molecular Sciences|February 11, 2023
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry ImagingJuliana Pereira Lopes Gonçalves, Christine Bollwein, Aurelia Noske, et al.
Pageof 11